By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Investment firm Jefferies today resumed coverage on eight molecular diagnostics, genetic testing, and life science tools firms.

Companies that Jefferies rated with a "Buy" are Myriad Genetics with a share price target of $26; Cepheid with a price target of $30; Gen-Probe with a price target of $75; Complete Genomics with a price target of $13; and Exact Sciences with a price target of $7.50.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.